Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Expression-Based Cell Lineage Analysis in Drosophila Through a Course-Based Research Experience for Early Undergraduates.

Olson JM, Evans CJ, Ngo KT, Kim HJ, Nguyen JD, Gurley KGH, Ta T, Patel V, Han L, Truong-N KT, Liang L, Chu MK, Lam H, Ahn HG, Banerjee AK, Choi IY, Kelley RG, Moridzadeh N, Khan AM, Khan O, Lee S, Johnson EB, Tigranyan A, Wang J, Gandhi AD, Padhiar MM, Calvopina JH, Sumra K, Ou K, Wu JC, Dickan JN, Ahmadi SM, Allen DN, Mai VT, Ansari S, Yeh G, Yoon E, Gon K, Yu JY, He J, Zaretsky JM, Lee NE, Kuoy E, Patananan AN, Sitz D, Tran P, Do MT, Akhave SJ, Alvarez SD, Asem B, Asem N, Azarian NA, Babaesfahani A, Bahrami A, Bhamra M, Bhargava R, Bhatia R, Bhatia S, Bumacod N, Caine JJ, Caldwell TA, Calica NA, Calonico EM, Chan C, Chan HH, Chang A, Chang C, Chang D, Chang JS, Charania N, Chen JY, Chen K, Chen L, Chen Y, Cheung DJ, Cheung JJ, Chew JJ, Chew NB, Chien CT, Chin AM, Chin CJ, Cho Y, Chou MT, Chow KK, Chu C, Chu DM, Chu V, Chuang K, Chugh AS, Cubberly MR, Daniel MG, Datta S, Dhaliwal R, Dinh J, Dixit D, Dowling E, Feng M, From CM, Furukawa D, Gaddipati H, Gevorgyan L, Ghaznavi Z, Ghosh T, Gill J, Groves DJ, Gurara KK, Haghighi AR, Havard AL, Heyrani N, Hioe T, Hong K, Houman JJ, Howland M, Hsia EL, Hsueh J, Hu S, Huang AJ, Huynh JC, Huynh J, Iwuchukwu C, Jang MJ, Jiang AA, Kahlon S, Kao PY, Kaur M, Keehn MG, Kim EJ, Kim H, Kim MJ, Kim SJ, Kitich A, Kornberg RA, Kouzelos NG, Kuon J, Lau B, Lau RK, Law R, Le HD, Le R, Lee C, Lee C, Lee GE, Lee K, Lee MJ, Lee RV, Lee SHK, Lee SK, Lee SD, Lee YJ, Leong MJ, Li DM, Li H, Liang X, Lin E, Lin MM, Lin P, Lin T, Lu S, Luong SS, Ma JS, Ma L, Maghen JN, Mallam S, Mann S, Melehani JH, Miller RC, Mittal N, Moazez CM, Moon S, Moridzadeh R, Ngo K, Nguyen HH, Nguyen K, Nguyen TH, Nieh AW, Niu I, Oh SK, Ong JR, Oyama RK, Park J, Park YA, Passmore KA, Patel A, Patel AA, Patel D, Patel T, Peterson KE, Pham AH, Pham SV, Phuphanich ME, Poria ND, Pourzia A, Ragland V, Ranat RD, Rice CM, Roh D, Rojhani S, Sadri L, Saguros A, Saifee Z, Sandhu M, Scruggs B, Scully LM, Shih V, Shin BA, Sholklapper T, Singh H, Singh S, Snyder SL, Sobotka KF, Song SH, Sukumar S, Sullivan HC, Sy M, Tan H, Taylor SK, Thaker SK, Thakore T, Tong GE, Tran JN, Tran J, Tran TD, Tran V, Trang CL, Trinh HG, Trinh P, Tseng HH, Uotani TT, Uraizee AV, Vu KKT, Vu KKT, Wadhwani K, Walia PK, Wang RS, Wang S, Wang SJ, Wiredja DD, Wong AL, Wu D, Xue X, Yanez G, Yang YH, Ye Z, Yee VW, Yeh C, Zhao Y, Zheng X, Ziegenbalg A, Alkali J, Azizkhanian I, Bhakta A, Berry L, Castillo R, Darwish S, Dickinson H, Dutta R, Ghosh RK, Guerin R, Hofman J, Iwamoto G, Kang S, Kim A, Kim B, Kim H, Kim K, Kim S, Ko J, Koenig M, LaRiviere A, Lee C, Lee J, Lung B, Mittelman M, Murata M, Park Y, Rothberg D, Sprung-Keyser B, Thaker K, Yip V, Picard P, Diep F, Villarasa N, Hartenstein V, Shapiro C, Levis-Fitzgerald M, Jaworski L, Loppato D, Clark IE, Banerjee U.

G3 (Bethesda). 2019 Nov 5;9(11):3791-3800. doi: 10.1534/g3.119.400541.

2.

Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2.

McInnes IB, Chakravarty SD, Apaolaza I, Kafka S, Hsia EC, You Y, Kavanaugh A.

RMD Open. 2019 Aug 18;5(2):e000990. doi: 10.1136/rmdopen-2019-000990. eCollection 2019.

3.

Efficacy and safety of intravenous golimumab plus methotrexate in patients with rheumatoid arthritis aged < 65 years and those ≥ 65 years of age.

Tesser J, Kafka S, DeHoratius RJ, Xu S, Hsia EC, Turkiewicz A.

Arthritis Res Ther. 2019 Aug 20;21(1):190. doi: 10.1186/s13075-019-1968-x.

4.

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase 2 Trial.

Helliwell PS, Deodhar A, Gottlieb AB, Boehncke WH, Xu XL, Xu S, Wang Y, Hsia EC, Gladman DD, Ritchlin CT.

Arthritis Care Res (Hoboken). 2019 Aug 17. doi: 10.1002/acr.24046. [Epub ahead of print]

PMID:
31421033
5.

Efficacy and Safety of Intravenous Golimumab through 1 Year in Patients with Active Psoriatic Arthritis.

Husni ME, Kavanaugh A, Murphy F, Rekalov D, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.

Arthritis Care Res (Hoboken). 2019 Apr 12. doi: 10.1002/acr.23905. [Epub ahead of print]

PMID:
30980514
6.

Safety and Efficacy of Intravenous Golimumab in Adults with Ankylosing Spondylitis: Results through 1 Year of the GO-ALIVE Study.

Reveille JD, Deodhar A, Caldron PH, Dudek A, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.

J Rheumatol. 2019 Oct;46(10):1277-1283. doi: 10.3899/jrheum.180718. Epub 2019 Mar 1.

7.

Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.

Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC.

J Rheumatol. 2019 Jun;46(6):595-602. doi: 10.3899/jrheum.180681. Epub 2019 Feb 15.

8.

Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G.

Rheumatology (Oxford). 2019 Mar 1;58(3):441-446. doi: 10.1093/rheumatology/key309.

PMID:
30412238
9.

Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis.

Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D.

Arthritis Rheumatol. 2019 Feb;71(2):258-270. doi: 10.1002/art.40728. Epub 2018 Dec 29.

10.

Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.

Deodhar A, Gottlieb AB, Boehncke WH, Dong B, Wang Y, Zhuang Y, Barchuk W, Xu XL, Hsia EC; CNTO1959PSA2001 Study Group.

Lancet. 2018 Jun 2;391(10136):2213-2224. doi: 10.1016/S0140-6736(18)30952-8. Epub 2018 Jun 1.

PMID:
29893222
11.

Reduction in ultraviolet B light-induced erythema by oxymetazoline and brimonidine is mediated by different α-adrenoceptors.

Hsia E, Tian M, Gil D.

Exp Dermatol. 2018 Jul;27(7):763-768. doi: 10.1111/exd.13557. Epub 2018 May 10.

PMID:
29637626
12.

Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study.

Deodhar A, Reveille JD, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.

J Rheumatol. 2018 Mar;45(3):341-348. doi: 10.3899/jrheum.170487. Epub 2017 Dec 15. Erratum in: J Rheumatol. 2018 Feb;45(2):291.

13.

Hedgehog mediated degradation of Ihog adhesion proteins modulates cell segregation in Drosophila wing imaginal discs.

Hsia EYC, Zhang Y, Tran HS, Lim A, Chou YH, Lan G, Beachy PA, Zheng X.

Nat Commun. 2017 Nov 2;8(1):1275. doi: 10.1038/s41467-017-01364-z.

14.

CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study.

Mease PJ, Jeka S, Jaller JJ, Kitumnuaypong T, Louthrenoo W, Mann H, Matsievskaia G, Soriano ER, Jia B, Wang C, Nie J, Hsia E.

J Rheumatol. 2018 Jan;45(1):22-31. doi: 10.3899/jrheum.161238. Epub 2017 Nov 1.

15.

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty-Four of the GO-VIBRANT Study.

Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Leu JH, Hsia EC.

Arthritis Rheumatol. 2017 Nov;69(11):2151-2161. doi: 10.1002/art.40226.

16.

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J.

J Rheumatol. 2016 Dec;43(12):2120-2130. Epub 2016 Nov 1.

18.

Efficacy and safety of golimumab in Indian patients with rheumatoid arthritis: Subgroup data from GO-MORE study.

Pal S, Veeravalli SC, Das SK, Shobha V, Uppuluri RR, Dharmanand BG, Nadkar M, Hsia E, Fei K, Yao R, Khalifa A.

Int J Rheum Dis. 2016 Nov;19(11):1083-1092. doi: 10.1111/1756-185X.12927. Epub 2016 Jul 26.

PMID:
27457311
19.

Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.

Keystone EC, Genovese MC, Hall S, Bae SC, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.

J Rheumatol. 2016 Feb;43(2):298-306. doi: 10.3899/jrheum.150712. Epub 2015 Dec 15.

PMID:
26669912
20.

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.

Emery P, Fleischmann RM, Strusberg I, Durez P, Nash P, Amante EJ, Churchill M, Park W, Pons-Estel B, Han C, Gathany TA, Xu S, Zhou Y, Leu JH, Hsia EC.

Arthritis Care Res (Hoboken). 2016 Jun;68(6):744-52. doi: 10.1002/acr.22759.

21.

Regulation of Hedgehog signaling by ubiquitination.

Hsia EY, Gui Y, Zheng X.

Front Biol (Beijing). 2015 Jun;10(3):203-220.

22.

Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.

Li Z, Zhang F, Kay J, Fei K, Han C, Zhuang Y, Wu Z, Hsia EC.

Int J Rheum Dis. 2016 Nov;19(11):1143-1156. doi: 10.1111/1756-185X.12723. Epub 2015 Aug 11.

PMID:
26259617
23.

Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.

Genovese MC, Hsia E, Belkowski SM, Chien C, Masterson T, Thurmond RL, Manthey CL, Yan XD, Ge T, Franks C, Greenspan A.

J Rheumatol. 2015 Oct;42(10):1752-60. doi: 10.3899/jrheum.141580. Epub 2015 Aug 1.

24.

The role of ciliary trafficking in Hedgehog receptor signaling.

Kim J, Hsia EY, Brigui A, Plessis A, Beachy PA, Zheng X.

Sci Signal. 2015 Jun 2;8(379):ra55. doi: 10.1126/scisignal.aaa5622.

25.

Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER study.

Smolen JS, Kay J, Doyle M, Landewé R, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Xu S, Zhou Y, Hsia EC.

Arthritis Res Ther. 2015 Jan 22;17:14. doi: 10.1186/s13075-015-0516-6.

26.

Simultaneous measurement of smoothened entry into and exit from the primary cilium.

Kim J, Hsia EY, Kim J, Sever N, Beachy PA, Zheng X.

PLoS One. 2014 Aug 13;9(8):e104070. doi: 10.1371/journal.pone.0104070. eCollection 2014.

27.

Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis.

Emery P, Fleischmann RM, Hsia EC, Xu S, Zhou Y, Baker D.

Clin Rheumatol. 2014 Sep;33(9):1239-46. doi: 10.1007/s10067-014-2731-y. Epub 2014 Jul 9.

PMID:
25005327
28.

Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.

Bao C, Huang F, Khan MA, Fei K, Wu Z, Han C, Hsia EC.

Rheumatology (Oxford). 2014 Sep;53(9):1654-63. doi: 10.1093/rheumatology/keu132. Epub 2014 Apr 11.

PMID:
24729398
29.

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation.

Lipianskaya J, Cohen A, Chen CJ, Hsia E, Squires J, Li Z, Zhang Y, Li W, Chen X, Xu H, Huang J.

Asian J Androl. 2014 Jul-Aug;16(4):541-4. doi: 10.4103/1008-682X.123669. Review.

30.

Effect of golimumab on carotid atherosclerotic disease measures and cardiovascular events in inflammatory arthritides.

Wasko MC, Hsia EC, Kirkham B, Touboul PJ, Fleischmann R, Genovese MC, Matteson EL, Lu J, Xu W, Rahman MU.

J Clin Rheumatol. 2014 Jan;20(1):1-10. doi: 10.1097/RHU.0000000000000053.

PMID:
24356481
31.

Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A.

Ann Rheum Dis. 2015 Mar;74(3):538-46. doi: 10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16.

32.

Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial.

Baker JF, Ostergaard M, Emery P, Hsia EC, Lu J, Baker DG, Conaghan PG.

Ann Rheum Dis. 2014 Nov;73(11):1968-74. doi: 10.1136/annrheumdis-2013-203444. Epub 2013 Jul 31.

PMID:
23904470
33.

Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.

Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.

Ann Rheum Dis. 2014 Oct;73(10):1811-8. doi: 10.1136/annrheumdis-2013-203435. Epub 2013 Jul 29.

35.

The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK.

Rheumatology (Oxford). 2013 Oct;52(10):1845-55. doi: 10.1093/rheumatology/ket233. Epub 2013 Jul 9.

36.

Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.

Keystone EC, Genovese MC, Hall S, Miranda PC, Bae SC, Palmer W, Wu Z, Xu S, Hsia EC.

J Rheumatol. 2013 Jul;40(7):1097-103. doi: 10.3899/jrheum.120584. Epub 2013 May 15.

37.

Neuroendocrine differentiation of prostate cancer.

Li Z, Chen CJ, Wang JK, Hsia E, Li W, Squires J, Sun Y, Huang J.

Asian J Androl. 2013 May;15(3):328-32. doi: 10.1038/aja.2013.7. Epub 2013 Mar 18. No abstract available.

38.

Evaluation of serum biomarkers associated with radiographic progression in methotrexate-naive rheumatoid arthritis patients treated with methotrexate or golimumab.

Wagner C, Chen D, Fan H, Hsia EC, Mack M, Emery P, Fleischmann RM.

J Rheumatol. 2013 May;40(5):590-8. doi: 10.3899/jrheum.120889. Epub 2013 Mar 1.

PMID:
23457387
39.

Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation.

Kirkham BW, Wasko MC, Hsia EC, Fleischmann RM, Genovese MC, Matteson EL, Liu H, Rahman MU.

Ann Rheum Dis. 2014 Jan;73(1):161-9. doi: 10.1136/annrheumdis-2012-202089. Epub 2013 Jan 7.

40.

Cystic fibrosis-related diabetes in adults: inpatient management of 121 patients during 410 admissions.

Rasouli N, Seggelke S, Gibbs J, Hawkins RM, Casciano ML, Cohlmia E, Taylor-Cousar J, Wang C, Pereira R, Hsia E, Draznin B.

J Diabetes Sci Technol. 2012 Sep 1;6(5):1038-44.

41.

Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in Phase III clinical trials.

Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, Xu S, Rahman MU.

Arthritis Care Res (Hoboken). 2013 Feb;65(2):309-13. doi: 10.1002/acr.21788.

42.

Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.

Hsia E, Seggelke S, Gibbs J, Hawkins RM, Cohlmia E, Rasouli N, Wang C, Kam I, Draznin B.

J Clin Endocrinol Metab. 2012 Sep;97(9):3132-7. doi: 10.1210/jc.2012-1244. Epub 2012 Jun 8.

PMID:
22685233
43.

Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study.

Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T, Murphy FT, Wu Z, Parasuraman S, Rahman MU.

J Rheumatol. 2012 Jun;39(6):1185-91. doi: 10.3899/jrheum.111195. Epub 2012 Apr 15.

PMID:
22505702
44.

Combination of Rad001 (everolimus) and propachlor synergistically induces apoptosis through enhanced autophagy in prostate cancer cells.

Tai S, Sun Y, Liu N, Ding B, Hsia E, Bhuta S, Thor RK, Damoiseaux R, Liang C, Huang J.

Mol Cancer Ther. 2012 Jun;11(6):1320-31. doi: 10.1158/1535-7163.MCT-11-0954. Epub 2012 Apr 5.

45.

Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160.

Smolen JS, Kay J, Landewé RB, Matteson EL, Gaylis N, Wollenhaupt J, Murphy FT, Zhou Y, Hsia EC, Doyle MK.

Ann Rheum Dis. 2012 Oct;71(10):1671-9. doi: 10.1136/annrheumdis-2011-200956. Epub 2012 Mar 29.

46.

Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis.

Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, Beutler A, Doyle MK, Hsu B, Rahman MU.

Arthritis Rheum. 2012 Jul;64(7):2068-77. doi: 10.1002/art.34382.

47.

Intensive control of diabetes in the hospital: why, how, and what is in the future?

Hsia E, Draznin B.

J Diabetes Sci Technol. 2011 Nov 1;5(6):1596-601.

48.

Comparison of 70/30 biphasic insulin with glargine/lispro regimen in non-critically ill diabetic patients on continuous enteral nutrition therapy.

Hsia E, Seggelke SA, Gibbs J, Rasouli N, Draznin B.

Nutr Clin Pract. 2011 Dec;26(6):714-7. doi: 10.1177/0884533611420727.

PMID:
22205560
50.

Exploratory analyses of the association of MRI with clinical, laboratory and radiographic findings in patients with rheumatoid arthritis.

Emery P, van der Heijde D, Ostergaard M, Conaghan PG, Genovese MC, Keystone EC, Fleischmann R, Hsia EC, Xu W, Xu S, Rahman MU.

Ann Rheum Dis. 2011 Dec;70(12):2126-30. doi: 10.1136/ard.2011.154500. Epub 2011 Sep 16.

Supplemental Content

Support Center